Abstract: The present disclosure provides nucleic acid sequences and nucleic acid delivery constructs comprising “zip code” sequence(s) that home, target, cross a cytoplasm, and/or cross a nuclear membrane of a target cell (e.g., a diseased cell such as a cancer cell) or cell population (e.g., tissue), and integration sequence(s) that allow for integration of at least a portion of such nucleic acid or nucleic acid delivery system into a genome of such target cell. The present disclosure also provides non-naturally occurring nucleic acid constructs and delivery systems comprising such Zip Code and integration sequences as well as one or more cargo molecules that may be coupled covalently or non-covalently to such nucleic acid constructs and systems. Further provided herein are methods of diagnosing and treating diseases such as cancer using the target cell specific nucleic acid constructs and systems described herein.

Abstract: This disclosure relates to classifiers of NF-?B pathway activation, devices, and methods of use thereof. In certain embodiments, the disclosure relates to methods comprising measuring changes in expression of genes controlled by p105 in a sample providing a detected p105 controlled gene expression pattern. In certain embodiments, the methods further comprise measuring changes in expression of genes controlled by p100 in a sample providing a detected p100 controlled gene expression pattern. In certain embodiments, the methods further comprise the step of comparing the detected p105 controlled gene expression patterns to a predetermined gene pattern and/or the detected p100 controlled gene expression patterns to a predetermined pattern.

Abstract: Provided herein are methods for selecting use of proteasome inhibitors.

Abstract: This disclosure relates to classifiers of NF-?B pathway activation, devices, and methods of use thereof. In certain embodiments, the disclosure relates to methods comprising measuring changes in expression of genes controlled by p105 in a sample providing a detected p105 controlled gene expression pattern. In certain embodiments, the methods further comprise measuring changes in expression of genes controlled by p100 in a sample providing a detected p100 controlled gene expression pattern. In certain embodiments, the methods further comprise the step of comparing the detected p105 controlled gene expression patterns to a predetermined gene pattern and/or the detected p100 controlled gene expression patterns to a predetermined pattern.

Abstract: This disclosure relates to classifiers of NF-?B pathway activation, devices, and methods of use thereof. In certain embodiments, the disclosure relates to methods comprising measuring changes in expression of genes controlled by p105 in a sample providing a detected p105 controlled gene expression pattern. In certain embodiments, the methods further comprise measuring changes in expression of genes controlled by p100 in a sample providing a detected p100 controlled gene expression pattern. In certain embodiments, the methods further comprise the step of comparing the detected p105 controlled gene expression patterns to a predetermined gene pattern and/or the detected p100 controlled gene expression patterns to a predetermined pattern.

Abstract: Provided herein are methods for selecting use of proteasome inhibitors.